PELLETIER: With the medical device market at $200 billion and an expected growth rate of 8 to 10 percent per year, potential for Ximedica is huge.

PELLETIER: In the past, Item New Product Development was primarily focused on design and development with a commercial and consumer focus. The creation and launch of Ximedica allows us to address the medical device industry and include sourcing, assembly, packaging, distribution and customer relationship management. This requires a separate system of compliance to meet FDA regulations, which is not required by Item New Product Development.